Abstract
AKT (or protein kinase B) and focal adhesion kinase (FAK) are two important kinases that regulate various cellular functions. Each is overexpressed and/or aberrantly activated in diverse cancers. Several small molecular inhibitors targeting either AKT or FAK are in development or in clinical trials. It is well established that FAK is an upstream regulator of AKT signaling pathway in various cancer cell lines and in xenograft tumor models. However, very recent reports from our laboratory and others demonstrate that AKT can also directly regulate FAK through direct association and serine phosphorylation. This indicates that AKT and FAK may be dual therapeutic targets for pharmacologic intervention in the treatment of primary and metastatic cancer. FAK-AKT interaction is particularly critical for metastatic adhesion. We review recent developments in AKT and FAK signaling in cancer with the particular emphasis on the novel signaling pathways in which FAK is downstream of AKT. We also provide an update on inhibitors targeting AKT or FAK currently in clinical trials.
Keywords: AKT, AKT1, AKT2, cancer, cancer metastasis, cell signaling, differentiation, FAK, FERM, invasion, isoform, migration, proliferation, Src
Anti-Cancer Agents in Medicinal Chemistry
Title: Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer
Volume: 11 Issue: 10
Author(s): Shouye Wang and Marc D. Basson
Affiliation:
Keywords: AKT, AKT1, AKT2, cancer, cancer metastasis, cell signaling, differentiation, FAK, FERM, invasion, isoform, migration, proliferation, Src
Abstract: AKT (or protein kinase B) and focal adhesion kinase (FAK) are two important kinases that regulate various cellular functions. Each is overexpressed and/or aberrantly activated in diverse cancers. Several small molecular inhibitors targeting either AKT or FAK are in development or in clinical trials. It is well established that FAK is an upstream regulator of AKT signaling pathway in various cancer cell lines and in xenograft tumor models. However, very recent reports from our laboratory and others demonstrate that AKT can also directly regulate FAK through direct association and serine phosphorylation. This indicates that AKT and FAK may be dual therapeutic targets for pharmacologic intervention in the treatment of primary and metastatic cancer. FAK-AKT interaction is particularly critical for metastatic adhesion. We review recent developments in AKT and FAK signaling in cancer with the particular emphasis on the novel signaling pathways in which FAK is downstream of AKT. We also provide an update on inhibitors targeting AKT or FAK currently in clinical trials.
Export Options
About this article
Cite this article as:
Wang Shouye and D. Basson Marc, Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (10) . https://dx.doi.org/10.2174/187152011797927661
DOI https://dx.doi.org/10.2174/187152011797927661 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gemini Surfactant Based Carriers in Gene and Drug Delivery
Current Medicinal Chemistry Flavonoids, Breast Cancer Chemopreventive and/or Chemotherapeutic Agents
Current Medicinal Chemistry Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy
Current Drug Metabolism Akt Pathway Inhibitors
Current Topics in Medicinal Chemistry Ovarian Cancer - Angiogenesis and Targeted Therapy
Current Angiogenesis (Discontinued) Heterocyclic Curcumin Derivatives of Pharmacological Interest: Recent Progress
Current Topics in Medicinal Chemistry Effects of LPA and S1P on the Nervous System and Implications for Their Involvement in Disease
Current Drug Targets Overview of Brain Tumor Stem Cells – Implications for Treatment
Current Signal Transduction Therapy The PIK3CA Gene as a Mutated Target for Cancer Therapy
Current Cancer Drug Targets Oxidation Chemistry of Catecholamines and Neuronal Degeneration: An Update
Current Medicinal Chemistry Novel Phospholipid-Based Labrasol Nanomicelles Loaded Flavonoids for Oral Delivery with Enhanced Penetration and Anti-Brain Tumor Efficiency
Current Drug Delivery Vasculogenic and Angiogenic Pathways in Moyamoya Disease
Current Medicinal Chemistry Lentiviral Vectors: A Versatile Tool to Fight Cancer
Current Molecular Medicine Kinase Inhibitors with Redox and Anti-inflammatory Activities
Current Topics in Medicinal Chemistry Biochemistry and Biology of 2'-Fluoro-2'-Deoxythymidine (FT), A Putative Highly Selective Substrate for Thymidine Kinase Type 2 (TK2)
Current Radiopharmaceuticals Heterocyclic Amaryllidaceae Alkaloids: Biosynthesis and Pharmacological Applications
Current Topics in Medicinal Chemistry Strategies to Overcome Multi-Drug Resistance in Cancer Cells: the Contribution of siRNA and Nanotechnologies
Current Organic Chemistry Natural Molecules as Talented Inhibitors of Nucleotide Pyrophosphatases/ Phosphodiesterases (PDEs)
Current Topics in Medicinal Chemistry Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice
Current Cancer Drug Targets